Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT trial)

Kuchay, Mohammad Shafi, Krishan, Sonal, Mishra, Sunil Kumar, Farooqui, Khalid Jamal, Singh, Manish Kumar, Wasir, Jasjeet Singh, Bansal, Beena, Kaur, Parjeet +4 more·2018·Diabetes Care
DOI 10.2337/dc18-0165

Cited by (657)

Items 601–657 of 657

  1. Efficacy of Empagliflozin in Fibrosis Progression in Patients with Type 2 Diabetes Mellitus Having Metabolic Dysfunction-Associated Steatotic Liver Disease
    Javed Imran, Hafsa Hassan, Tanjina Zannat, Parijat Ghosh, Faria Afsana, MG Azam, Mohammod Feroz Amin, Md Faruque Pathan · 2026 · Bangladesh Journal of Endocrinology and Metabolism
  2. Treatment Modalities for Hepatic Steatosis and Fibrosis in Type 2 Diabetes: A Review Article
    Varun Anil Damle, Akarshan Sharma, Brijendra Kumar Srivastava, Arkiath Veettil Raveendran, Krishna G. Seshadri, Viswanathan Mohan · 2026 · Journal of Diabetology
  3. Decoupling weight loss from organoprotective benefits in GLP-1RA, dual agonists, and SGLT2I therapy: A narrative review
    Gaurab Bhaduri, SUPRATIK BHATTACHARYYA, Shatavisa Mukherjee, Rutul A. Gokalani · 2026 · Acta Diabetologica
  4. Comparative efficacy of SGLT2 Inhibitors and Obeticholic Acid in MAFLD and Fibrosis: A Systematic Review
    Thenmozhi Ganesh, Vignesh subramani, Rajesh kannan.S, Yuvaraj.G · 2026 · Research Square
  5. Probiotics for managing non-alcoholic fatty liver disease: efficacy and mechanistic insights
    Supriyo Ghosh, Amlan Jyoti Ghosh, Manab Deb Adhikari, Bipransh Kumar Tiwary, Tilak Saha · 2026 · Journal of Diabetes & Metabolic Disorders
  6. Impact of empagliflozin on liver fat reduction in type 2 diabetes and NAFLD: A systematic review and meta-analysis
    Muhammad Umais, Hooriah Imtiaz, Muhammad Shaheer Luqman, Sidra Anwar, Muhammad Umer Iftikhar, Kanwal Maheshwari, Zarine Tasnim Sara, Noor ul Huda Naseem, Firose Afra Ibnath, Abdul Rehman Shah Syed et al. · 2026 · Endocrine
  7. Focal Hepatic Steatosis Mimicking a Hilar Tumor With Rapid Resolution After Glycemic Control: A Case Report
    Hiroteru Kamimura, Hiroshi Suzuki, Azusa Sone, Makoto Miyazawa, Yuzo Kawata, Yuko S Komoro, Yosuke Horii, Takanori Tsujimura, Hirohito Sone, Shuji Terai · 2026 · Cureus
  8. SGLT2 İnhibitörleri ile Tedavi Edilen Tip 2 Diyabet Hastalarında FIB-4 Seyri ve Karaciğer Fibrozis Yanıtının Belirleyicileri: Eşleştirilmiş Örneklemle 12 Aylık Bir Çalışma
    Nazif Yalçın, Ayşegül Ertınmaz, Gizem Zorlu Görgülügil, Nizameddin Koca · 2025 · DergiPark (Istanbul University)
  9. SGLT2 inhibitors preserve serum chloride in non-diabetic CKD: a propensity-matched and LASSO regression analysis
    Masaru Matsui, Takaaki Kosugi, Shunsuke Kitamura, Masatoshi Nishimoto, Akiko Itano, Marumi Yamamoto, Haruka Yabuta, Aiko Oda, Masato Kawakami, Hideo Tsushima et al. · 2026 · Renal Failure
  10. From HBV to MASLD Cirrhosis: Mechanistic Insights and Therapeutic Strategies
    Hanqi Yu, Hongfan Ding, Yang Huang, Haoze Cao, Yuan Ding, Weilin Wang · 2026 · Portal hypertension & cirrhosis
  11. Dapagliflozin Plus Metformin Versus Metformin Alone in Overweight and Obese Patients with Polycystic Ovary Syndrome - An Open-Label, Parallel, Randomized Controlled Trial
    Vishal Agarwal, Sambit Das, Arun Kumar Choudhury, Dayanidhi Meher, Devadarshini Sahoo, Sandeep K Sahu, Subhadra Priyadarshini, Sonam Jalewa Agarwal, Binod Prusty, Bijay K. Das et al. · 2026 · Indian Journal of Endocrinology and Metabolism
  12. Beyond Glucose Control: A Comprehensive Review of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors in Heart Failure, Chronic Kidney Disease, and Nonalcoholic Fatty Liver Disease
    Alexander Sosa, Michael C Sosa · 2026 · Cureus
  13. Role of Sodium-glucose Cotransporter-2 Inhibitors in Metabolic Dysfunction-associated Steatotic Liver Disease in Type 2 Diabetes
    Abul B. M. Kamrul-Hasan · 2026 · Bangladesh Journal of Endocrinology and Metabolism
  14. Cholesterol: an ancient ally or modern menace?
    Ismael Luna-Reyes, Stephanie Villa-Jaimes, Sandra Calixto-Tlacomulco, Eréndira Guadalupe Pérez-Hernández, Danai Montalvan‐Sorrosa, Juan Pablo Reyes‐Grajeda, Jaime Mas‐Oliva · 2026 · Royal Society Open Science
  15. Association of Metabolic Dysfunction-Associated Steatohepatitis with Metabolic-Related Diseases
    Leonidas Nikolaos Diamantopoulos, Markos Kalligeros, Scott D. Isaacs, Dı́dac Mauricio · 2026 · Clinics in Liver Disease
  16. Potential of Glucagon-like peptide-1 receptor agonists (GLP1a) and Sodium-Glucose Co-transporter-2 inhibitors (SGLT2i) in the treatment of MASLD
    Anna Török Zapletalová, Boris Focko, Martin Jozef Péč, Daniel Ján Havaj, Ľubomír Skladaný, Emil Martinka, Péter Galajda · 2025 · Vnitřní lékařství
  17. The Liver-Heart Axis: A Narrative Review of Clinical Implications of the MASLD Redefinition for Internists
    Hassan A. Abdou, Saied A. Omar · 2026 · ASIDE Gastroenterology
  18. Treatment of Modifiable Risks in Metabolic Dysfunction-Associated Steatotic Liver Disease
    Sonal Kumar, Maria Paula Macedo, Michael Roden, Sangeeta Rao Kashyap · 2026 · Clinics in Liver Disease
  19. Metabolic changes induced by dapagliflozin, an SGLT2 inhibitor, in Japanese patients with type 2 diabetes treated by oral anti-diabetic agents: A randomized, clinical trial
    佳代 堀部, Katsutaro Morino, Itsuko Miyazawa, Keiko Kondo, Daisuke Sato, 夏子 大橋, 昌吾 井田, 剛司 柳町, 雅寛 吉村, 井藤, 隆太 et al. · Institutional Repositories DataBase (IRDB)
  20. High-fat diet, gut dysbiosis, and oxidative stress: A synergistic triangle in metabolic dysfunction-associated steatotic liver disease pathogenesis
    Zi-Rui Zhang, Ling She, Yirong Cao, Yuan-Wen Chen · 2026 · World Journal of Hepatology
  21. A narrative review of sarcopenia in patients with cardiovascular kidney metabolic syndrome: Another brick in the wall?
    Barış Afşar, Mehmet Kanbay, Rengin Elsürer Afşar · 2026 · Clinical Nutrition
  22. Diabetes and Obesity as Catalysts in MASH Progression: Mechanisms and Emerging Therapies
    Bhumika Munda, Chimila Bhutia, Deepti, Manisha Khatri · 2026 · Letters in Applied NanoBioScience
  23. Dissecting out the unexpected effects of SGLT2 inhibitors on human aging
    Goro Katsuumi, Tohru Minamino · 2026 · The Journal of Clinical Endocrinology & Metabolism
  24. Impact of modern glucose-lowering therapies on metabolic dysfunction-associated steatotic liver disease in type 2 diabetes
    A. M. Urbanovych, N.Ya. Sidelnyk, Orysia Lishchuk · 2026 · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
  25. Effect of dapagliflozin in liver transplant recipients with chronic kidney disease
    Christiana Graf, Nicholas Zeuzem, Alina Bauschen, Julian Allgeier, Gerald Denk, Christiane Paulig, Stephan Kemmner, Markus Otto Guba, Christian Markus Lange · 2026 · Journal of Liver Transplantation
  26. Effectiveness of sodium–glucose cotransporter 2 inhibitors in patients with metabolic dysfunction-associated steatotic liver disease: systematic review and meta-analysis of randomized controlled trials
    Milena Ramos Tomé, Jingying Elena Chen, Alana Vitória Santos de Jesus, Wellgner Fernandes Oliveira Amador, Gustavo Procópio Silva, Igor Boechat Silveira, Arthur Victor de Holanda Sampaio, Guilherme Grossi Lopes Cançado · 2026 · European Journal of Gastroenterology & Hepatology
  27. From kidney to liver: Are sodium–glucose cotransporter-2 inhibitors emerging as metabolic disease modifiers?
    Sydney Mpisa, Jonathan Soldera · 2026 · World Journal of Nephrology
  28. Effects of SGLT-2 inhibitors and GLP-1 receptor agonists on liver function in patients with non-alcoholic fatty liver disease and type 2 diabetes
    Wancheng Guo, Wenhe Li, Xianlin Li, Wen Shi, Yan Yan, Ting Yan, Jie Zhou, Yujie Huang · 2026 · Frontiers in Endocrinology
  29. Enavogliflozin Improves Non‐invasive Hepatic Steatosis Indices in Patients With Type 2 Diabetes: A Pooled Analysis of Three Randomised Trials
    Min Kyoung Jang, Chang Hee Jung, Han Sol Lee, Areum Lee, Su‐Jin Jeoung, Yong‐ho Lee, Hae Jin Kim, So Hun Kim, Sung Hoon Yu, Suk Chon et al. · 2026 · Diabetes Obesity and Metabolism
  30. Impatto degli SGLT2i sulla MASLD in pazienti con diabete mellito tipo 2
    Natascia Tahani, Massimiliano Caprio · 2026 · L Endocrinologo
  31. Pharmacological treatment of metabolic dysfunction–associated steatotic liver disease: a narrative review
    Jeong-Hwan Lee, Jeong‐Ju Yoo, Sang Gyune Kim, Young Seok Kim · 2026 · Journal of Korean Medical Association
  32. Real-world efficacy and safety of SGLT2 inhibitor add-on triple therapy in south indian patients with type 2 diabetes mellitus: a 24-week prospective observational cohort study
    Ananya Ginjupalli, Sreeram Thiriveedhi, Pavan Sai Nelluri, Sai Sravanth Reddy Tamma, Gitanjali Boppana, Suman Maharjan · 2026 · Diabetology & Metabolic Syndrome
  33. Pharmacologic Treatments for MASLD: A Review of Efficacy and Safety Considerations
    Jonathan S. Newsome · 2026 · Journal of Pharmacy Technology
  34. Hepatoprotective effects of empagliflozin in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis of preclinical studies
    Lashin S. Ali, Mohamed O. Mostafa, Dana K. Alsharayiah, Mohamed Atef Elkholy, Khaled A. Ahmed, Ahmed A. El‐Mansy, Abd El Rahman M Sharfeldeen, Gehan Elwakeel, Abdelnaser A. Badawy, Ahmed Hamad Ahmed Sulaiman et al. · 2026 · Frontiers in Pharmacology
  35. Efficacy of Empagliflozin on Liver Enzymes, Lipid Profile and BMI in Patients With Metabolic Dysfunction–Associated Steatotic Liver Disease ( MASLD ): A Systematic Review and Meta‐Analysis
    Mehdi Karimi, Ali Tahmasebi, Sepehr Ramezanipour, Fatemeh Naseri Rad, Fereshteh Valizadeh, Pegah Abedi, Meisam Gholami, Narges Sobhan Ardekani, Manijeh Ebrahimzadeh Pirshahid · 2026 · Endocrinology Diabetes & Metabolism
  36. Heart-liver co-management: epidemiology, mechanisms, and novel therapeutic approaches for metabolic dysfunction-associated steatotic liver disease and coronary artery disease
    Sirui Zhu, Fangkun Yang, Haoxuan Lu, Jun Jiang, He WQ · 2026 · Frontiers in Cardiovascular Medicine
  37. Selective SGLT2 inhibitors in MASLD/MASH: an outcome-specific systematic review and meta-analysis of hepatic and cardiometabolic outcomes
    Danilo Caponio, Giuseppina Alessia Acucella, Michele Acucella · 2026 · Acta Diabetologica
  38. Risk stratification of MASLD/MASH in type 2 diabetes: a pragmatic endocrinology outpatient pathway
    Yulan Cai, Feng Zeng, Chuyu Liu · 2026 · Frontiers in Endocrinology
  39. Empagliflozin in the Absence of Diabetes: A Systematic Review of Its Anthropometric and Metabolic Effects in Humans and Animals
    Farima Farsi, Dorsa Ghorban Sarvi, Mohammadmahdi Abbasi, Shirin Hasani‐Ranjbar · 2026 · International Journal of Endocrinology
  40. Efficacy and safety of empagliflozin in metabolic dysfunction–associated steatotic liver disease: A systematic review and meta-analysis
    Shambo Samrat Samajdar, Shashank Joshi, Gaurab Bhaduri, Banshi Saboo, Krishnendu Roy, Shatavisa Mukherjee, Snehal Bansode, Sanjay Bandyopadhyay · 2026 · Clinics and Research in Hepatology and Gastroenterology
  41. Sodium Glucose Cotransporter 2 Inhibitor Use in Diabetic Patients With Cirrhosis Improves Liver-Related Outcomes and Survival
    Sajid Jalil, Khurram Bari, Khalid Mumtaz, Ahmed Ibrahim, Talal K Bhatti, Suvisesh Pothuraju, Mohammad Adam, Honor S. Magon, Nikki K. Duong, Paul Yien Kwo · 2026 · Clinical and Translational Gastroenterology
  42. Metabolic dysfunction–associated steatotic liver disease assessment and management: Clinical practice guidance from the Canadian Association for the Study of the Liver
    Mohit Kehar, Alnoor S. Ramji, Mark Swain, Alexander G. Singer, NOAH IVERS, Wendy Schaufert, Michael Betel, Kaberi Dasgupta, Giada Sebastiani, Keyur Patel · 2026 · Canadian Liver Journal
  43. Efficacy of Dapagliflozin vs. Saroglitazar on Hepatic Steatosis and Fibrosis in Patients of Type 2 Diabetes Mellitus and Metabolic-Associated Steatotic Liver Disease (MASLD)
    B K Das, Sambit Das, Dayanidhi Meher, Arun Kumar Choudhury, Sourav Padhee, Sandeep K Sahu, Devadarshini Sahoo, Binod Prusty, Vishal Agarwal · 2026 · Indian Journal of Endocrinology and Metabolism
  44. Fibrosis-Driven Cardiovascular Risk in Metabolic Dysfunction-Associated Steatotic Liver Disease: Emerging Links With Atherosclerotic Cardiovascular Disease
    Nakul Mahajan, Nazdeep Kaur, Samar Pal S. Sandhu, Vyoma Patel, Hunardeep Kaur Boparai, Kanwarmandeep Singh, FNU Rajinderpal Singh · 2026 · Cureus
  45. Incremental effects of SGLT2 inhibitors, GLP-1 receptor agonists, and pioglitazone in type 2 diabetes and MASLD across Asian study settings: a systematic review and meta-analysis
    Hanwen Zheng, Jieru Han · 2026 · Frontiers in Endocrinology
  46. Metabolic dysfunction-associated steatotic liver disease in people living with HIV: mechanisms, diagnosis, and management
    Ruoli Yu, Wei Xu, Jun Chen · 2026 · Frontiers in Immunology
  47. siRNA therapeutics for metabolic dysfunction-associated Steatohepatitis: Targets, delivery, clinical evidence, and translational challenges
    Yanan Guo, Qunyan Yao · 2026 · Biochemistry and Biophysics Reports
  48. Co-administration of empagliflozin and curcumin attenuates the development of MASLD by modulating lipid metabolism and adipose tissue browning in HFD-fed C57BL/6J mice
    Masoume Aliabadi, Ali Akbar Soleimani, Gholamreza Taheripak, Mitra Nourbakhsh, Reza Meshkani · 2026 · Life Sciences
  49. Comparative hepatic effectiveness of empagliflozin vs dapagliflozin among individuals with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease
    Suyeon Kim, Hwa Yeon Ko, Bin Hong, Jie‐Hyun Kim, Sungho Bea, Jae Hyun Bae, Young Min Cho, Yoosoo Chang, Christopher D. Byrne, Ju‐Young Shin · 2026 · Diabetologia
  50. Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis (MASLD/MASH) and Cardiovascular Risk: Emerging Therapeutic Strategies at the Interface of Liver and Cardiometabolic Disease
    Chrysoula Boutari, Konstantinos Charalampidis, Lazaros Sideras, Emmanouil Sinakos, Ioannis Goulis · 2026 · Life
  51. Insulin resistance and hepatic steatosis
    Anja Tomović, Nikola Bakovic, Ivana Pantić, Nevena Baljosevic, Ivan Ranković, Tamara Milovanovic Alempijevic · 2026 · Best Practice & Research Clinical Gastroenterology
  52. Pharmacotherapy for MASLD/MASH: approved therapies, drug repurposing, and emerging mechanism-based candidates
    Majid Mufaqam Syed‐Abdul · 2026 · Expert Opinion on Pharmacotherapy
  53. SGLT2 inhibitors in diabetic biopsy proven MASH patients: A systematic review and meta-analysis
    Mona S. Abdel Monem, Ahmed Mostafa Ahmed Kamel, Maggie Abbassi, Nirmeen Ahmed Sabry · 2026 · Journal of Diabetes and its Complications
  54. Anti-inflammatory versus metabolic therapy in MASLD: a randomized clinical trial of aspirin and dapagliflozin using fibroscan outcomes
    Eman Mostafa Hamed, Eman Hamza, Reham Abdullah Al-Dhelaan, Fahad T. Alsulami, Ahmed Mahmoud Khallaf, A Badran, Asmaa Saleh, Aya Anwar Mustafa Mahmoud · 2026 · Naunyn-Schmiedeberg s Archives of Pharmacology
  55. Pharmacotherapy for MASLD: current evidence and challenges in clinical practice
    Laura Pages, Diego Rojo, Alba Jiménez-Masip, Elena Tricarico, Eduard Mas‐Carrió, Anna Aguilar, Nerea Gómez, Lucia Molinero, Juan M Pericas · 2026 · Annals of Hepatology
  56. Efficacy and safety of GLP-1 receptor agonists in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH)
    Mohammed Abdullah Alfawaz, Dareen Bajamaan, Lama S. Alghamdi, Yara A Alorfi, Saud Khared, Nada Ameen, Rahaf Alamri, Mohammed Abuladel, Rayan Alshehri, Shaima Altowairqi · 2026 · Medicine
  57. BindingDB Entry 50007641: The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease.
    BindingDB · 2021 · UC San Diego